Opaleye Management Inc.
- Regulatory AUM
- $803M
- Discretionary
- $803M
- Clients
- 2
- Avg AUM / client
- $401M
- Accounts
- 2
- Employees
- 4
AUM over time
Annual snapshots from Form ADV filings · as of Feb 19, 2026
Investments (13F portfolio — 54 positions, $759,221,131)
13F period Mar 31, 2026| # | Issuer | Class | Value | Shares | % of 13F | % of AUM |
|---|---|---|---|---|---|---|
| 1 | Harrow Inc | COM | $99,864,430 | 2,832,230 | 13.2% | 12.4% |
| 2 | Liquidia Corporation | COM NEW | $88,820,500 | 2,545,000 | 11.7% | 11.1% |
| 3 | Eton Pharmaceuticals Inc | COM | $70,584,800 | 2,860,000 | 9.3% | 8.79% |
| 4 | Sol Gel Technologies Ltd | SHS NEW | $39,610,000 | 500,000 | 5.22% | 4.93% |
| 5 | Rhythm Pharmaceuticals Inc | COM | $35,323,200 | 123,000 | 4.65% | 4.4% |
| 6 | Apogee Therapeutics Inc | COM | $32,826,300 | 390,000 | 4.32% | 4.09% |
| 7 | Disc Medicine Inc | COM | $26,918,740 | 421,000 | 3.55% | 3.35% |
| 8 | Urogen Pharma Ltd | COM | $25,711,400 | 1,430,000 | 3.39% | 3.2% |
| 9 | Crescent Biopharma Inc. | COM | $24,112,738 | 1,312,615 | 3.18% | 3.0% |
| 10 | Stoke Therapeutics Inc | COM | $22,792,000 | 700,000 | 3.0% | 2.84% |
| 11 | Perspective Therapeutics Inc | COM NEW | $19,494,750 | 4,675,000 | 2.57% | 2.43% |
| 12 | Rezolute Inc | COM NEW | $19,215,000 | 6,300,000 | 2.53% | 2.39% |
| 13 | Meiragtx Hldgs Plc | COM | $18,387,423 | 2,123,259 | 2.42% | 2.29% |
| 14 | Tg Therapeutics Inc | COM | $17,772,700 | 535,000 | 2.34% | 2.21% |
| 15 | Sanuwave Health Inc | COM | $16,966,106 | 981,267 | 2.23% | 2.11% |
| 16 | Edgewise Therapeutics Inc | COM | $15,750,000 | 500,000 | 2.07% | 1.96% |
| 17 | Alpha Cognition Inc | COM NEW | $14,065,106 | 2,561,950 | 1.85% | 1.75% |
| 18 | Annexon Inc | COM | $12,917,956 | 2,331,761 | 1.7% | 1.61% |
| 19 | Alumis Inc | COM | $12,116,500 | 550,000 | 1.6% | 1.51% |
| 20 | Codexis Inc | COM | $11,059,550 | 6,785,000 | 1.46% | 1.38% |
| 21 | Protagonist Therapeutics Inc | COM | $10,540,000 | 100,000 | 1.39% | 1.31% |
| 22 | Revolution Medicines Inc | COM | $9,725,000 | 100,000 | 1.28% | 1.21% |
| 23 | Xoma Royalty Corporation | COM NEW | $9,411,000 | 300,000 | 1.24% | 1.17% |
| 24 | Q32 Bio Inc | COM | $8,064,984 | 1,256,228 | 1.06% | 1.0% |
| 25 | Mbx Biosciences Inc | COM | $7,761,000 | 260,000 | 1.02% | 0.97% |
Top 25 of 54 positions from the manager's latest Form 13F · source filing (EDGAR) ↗. 13F covers long US-listed positions only. "% of AUM" is share of the firm's total regulatory AUM (Form ADV Item 5.F).
Who they serve
| Client type | Clients | AUM | % of AUM |
|---|---|---|---|
| Pooled investment vehicles (non-investment companies) | 1 | $789M | 98.3% |
| Corporations and other businesses | 1 | $13.6M | 1.69% |
Private funds (1)
Reported in Form ADV Section 7.B.(1), filing of Mar 2024 · $422M combined gross assets
| Fund | Type | Domicile | Gross assets | Owners |
|---|---|---|---|---|
| Opaleye, L.P. | Hedge Fund | Delaware | $422M | 63 |
People (1)
| Name | Role / title | Credentials | With firm since | Ownership |
|---|---|---|---|---|
| Silverman, James, Aaron | President/Chief Compliance Officer | Feb 1996 (31y) | 75% or more |
Undisclosed: 0% – 25% of the firm is not attributable from the filed Schedule A bands.
Roster from the IAPD representatives feed; ownership and acquisition dates from Form ADV Schedule A/B. "Since" is the earliest filed registration or acquisition date.
Private funds (1, $422M gross assets)
| Fund | Type | Gross assets | Min. investment | Owners |
|---|---|---|---|---|
| Opaleye, L.P. | Hedge Fund | $422M | $300K | 63 |
From Form ADV Section 7.B private fund reporting.
Documents (1 archived)
| Form | Period | Size | |
|---|---|---|---|
| Form ADV (full filing) | 02/19/2026 | 1.28 MB | View · PDF · Source ↗ |
Archived copies of the firm's regulatory filings, versioned by content hash.
Disciplinary disclosures
Allegations: AN ADMINISTRATIVE COMPLAINT WAS BROUGHT ON MARCH 9, 2011 AGAINST JAMES A. SILVERMAN, RISK REWARD CAPITAL MANAGEMENT CORP., RRC MANAGEMENT, LLC AND RRC BIO FUND, LP ("RESPONDENTS") BY THE ENFORCEMENT SECTION OF THE MASSACHUSETTS SECURITIES DIVISION OF THE OFFICE OF THE SECRETARY OF THE COMMONWEALTH ("DIVISION"). THESE ENTITIES ARE NOW KNOWN AS OPALEYE MANAGEMENT INC., OPALEYE GP LLC AND OPALEYE, L.P. RESPECTIVELY. IN THE COMPLAINT, THE DIVISION ALLEGED A LACK OF PROCEDURES REGARDING MATERIAL NON-PUBLIC INFORMATION AND NON-COMPLIANCE WITH RESPECT TO MAINTENANCE OF BOOKS AND RECORDS. ON SEPTEMBER 24, 2014, THE PARTIES ENTERED INTO A CONSENT ORDER WHEREIN THEY AGREED TO SETTLE THE MATTER. RESPONDENTS NEITHER ADMITTED NOR DENIED THE ALLEGATIONS CONTAINED IN THE ORIGINAL COMPLAINT. Status: Final Sanction Detail: RESPONDENTS JOINTLY AND SEVERALLY PAID A FINE OF $50,000 ON OCTOBER 1, 2014. Summary: ON SEPTEMBER 24, 2014 , OPALEYE MANAGEMENT INC., OPALEYE GP LLC AND OPALEYE, L.P. ENTERED INTO A CONSENT ORDER ("ORDER") WHEREIN THEY AGREED TO SETTLE THIS MATTER. RESPONDENTS NEITHER ADMITTED NOR DENIED THE ALLEGATIONS CONTAINED IN THE ORIGINAL COMPLAINT. THE ORDER REQUIRED RESPONDENTS TO COMPLY WITH 203(A) AND 203A OF THE MASSACHUSETTS ACT AND MASSACHUSETTTS REGULATIONS, THAT RESPONDENTS VERIFY THAT BETWEEN OCTOBER 29, 2011 AND OCTOBER 29, 2013 THAT RESPONDENTS DID NOT USE ANY MATCHING OR EXPERT NETWORK SERVICES AND THAT THE RESPONDENTS PAY A FINE OF $50,000. THE ORDER DID NOT CONTAIN OR CONSTITUTE ANY LEGAL OR FACTUAL FINDINGS OR CONCLUSION, INCLUDING WITHOUT LIMITATION, ANY FINDING OF ANY VIOLATION OR LAW OR REGULATION THAT PROHIBITS FRAUDULENT, MANIPULATIVE OR DECEPTIVE CONDUCT AND PROVIDES NO STATUTORY DISQUALIFICATION.
Disclosure text reproduced verbatim from the firm's own Form ADV filings.
How they charge
- • Percentage of assets under management
- • Performance-based fees
Services
- • Portfolio management for pooled investment vehicles
- • Portfolio management for businesses/institutional clients
Custody
Reported custodians
- Btig, Llc $31.0M (5% of AUM) Apr 2022
Amounts as reported in ADV Item 5.K.(3) (custodians holding 10%+ of SMA assets).
Firm reports having custody of client funds or securities (Item 9.A).
Source
All data on this page comes from this firm's Form ADV filings, reproduced without modification. Latest filing: Feb 19, 2026.
View current Form ADV (SEC/IAPD) ↗